ARE — Alexandria Real Estate Equities

Is ARE overbought or oversold? Here is the current MarketMoodz read.

Real Estate · REIT - Office

Oversold As of November 17, 2026

Alexandria Real Estate Equities (ARE) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Real Estate name (REIT - Office) last closed at $42.38. The rating moved from Neutral to Oversold on November 17, 2026.

See all oversold Real Estate stocks →

AI analysis

Alexandria Real Estate Equities (ARE) is a life‑science–focused REIT with a differentiated urban lab portfolio and long‑dated lease structures that support predictable cash flows. Near term, sector sentiment is neutral with limited catalysts; upside depends on stabilization of capital markets and improving biotech funding/leasing trends, while downside would be driven by slower lease-up or tighter financing conditions. Social sentiment and recent filings provided little new directional evidence in the past trading window.

Key factors

  • Specialized life-sciences real estate franchise with high-quality urban lab campuses and long-term lease structures that support cash-flow visibility
  • Tenant base skewed to biotech and pharma firms, which can provide above-average rent resilience when sector funding and hiring are healthy
  • Demonstrated balance-sheet optionality for large REITs and access to long-dated capital markets, which supports refinancing flexibility
  • Development pipeline and infill lab conversion opportunities in core life-science clusters that can drive NOI growth if leasing velocity recovers
  • Current macro and sector tone is neutral; limited near-term catalysts but steady demand themes for life-science space remain intact
  • Dividend yield and income profile attract income-oriented investors in a low-volatility environment

Risks

  • Interest-rate and broader capital-market volatility increasing borrowing costs, compressing NAV and redevelopment returns
  • Slower-than-expected leasing velocity in life-science markets leading to rising vacancy and concession pressure
  • Tenant concentration and exposure to starts/VC funding cycles in biotech that can amplify rent roll risk if capital markets tighten
  • Execution risk on developments and lab conversions (cost overruns, slower lease-up) that could pressure cash flows
  • Refinancing timing and maturity wall risk if markets tighten unexpectedly despite broadly available long‑dated capital
  • Macroeconomic slowdown or reduced corporate R&D spending that disproportionately affects lab demand

See today's live rating, score and targets

Members see the live hourly rating for ARE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.